Global Hospital-at-Home Market Outlook to 2032

Executive Summary

Hospital-at-home delivers inpatient-acuity care in patients' homes using remote monitoring, mobile clinical teams, and 24/7 escalation infrastructure. The global market is forecast to grow from US$5 billion in 2024 to US$35 billion by 2032, a 28% CAGR.

The category is no longer waiver-dependent pilot. Three forces converged in 2025–26: the Consolidated Appropriations Act of 2026 (signed February 2026) extended the CMS Acute Hospital Care at Home waiver five years to September 30, 2030; participating-hospital count grew 31% in 17 months to 419 hospitals across 147 health systems and 39 states; and operators with healthcare-system DNA replaced consumer-tech entrants after Best Buy Health's 2024 exit. The binding constraint through 2030 is no longer regulatory; it is workforce supply and Medicaid coverage in the 38 states that still do not reimburse for fee-for-service enrollees.

Market Overview

hospital-at-home scope captures the integrated value chain: hospital-trained clinical workforce delivered to homes, remote-monitoring devices, video consultation, mobile diagnostics, 24/7 emergency-response infrastructure, and the DRG-based payment plumbing that makes acute home-care economically equivalent to an inpatient stay. The category is distinct from traditional home health, which serves lower-acuity patients on a different reimbursement model.

Three structural drivers underpin growth. First, hospital-system economics favour hospital-at-home over capital-intensive bed expansion: an average inpatient bed costs US$2.0 million to US$4.0 million to build, while a hospital-at-home "virtual bed" runs US$50,000 to US$150,000 once technology and workforce are in place. Each virtual bed serves roughly 0.7 to 0.8 patient-equivalent annually. Second, the US population aged 65 and over grows from 58 million (2024) to 73 million (2032), and the hospital-at-home clinical pathways (CHF, COPD, pneumonia, cellulitis, UTI) overweight that cohort. Third, CMS-tracked outcomes from the AHCAH waiver show patient-experience scores 15 to 25 percentage points above inpatient and 30-day readmissions 4 to 8 points lower, which de-risks payer expansion.

Market Size and Growth Outlook

The 2024–28 phase compounds at more than 33% growth as the CMS five-year extension unlocks multi-year capital allocation and Medicaid fee-for-service coverage expands beyond the 12 states currently reimbursing. Growth moderates to roughly 18% by 2032 as participating-hospital and patient-volume bases reach scale and global episode volume approaches one million per year.

Market Segmentation

By Clinical Pathway

Cardiovascular and respiratory pathways together drive 52% of patient-episode volume because these conditions have the most evidence-based hospital-at-home protocols and the largest available patient population. Oncology supportive care is the fastest-growing pathway, expanding from a small base on CAR-T cytokine release syndrome management at home and chemotherapy supportive-care models.

By Payer

Medicare fee-for-service at 38% is the binding payer cohort and the reason the CMS waiver extension matters so much. Medicaid coverage is the largest unaddressed opportunity: only 12 state Medicaid agencies (Arizona, Arkansas, Massachusetts, Michigan, New York, New Jersey, North Carolina, Oregon, Oklahoma, South Carolina, South Dakota, Texas) currently reimburse for fee-for-service enrollees. Medicare Advantage plan-specific contracts grew from a handful in 2022 to over 80 by end-2025 and is the fastest-growing US payer channel.

By Region

The US leads in 2024 dollar value but the UK NHS @home programme is targeting 500,000 virtual-ward patients per year by 2027, which makes Europe the fastest-growing region in absolute terms. India is the highest-growth percentage region, anchored by Apollo, Practo, and Portea, but on a small base and serving primarily out-of-pocket private patients.

Trends and Developments

CMS waiver five-year extension

The Consolidated Appropriations Act of 2026 (signed February 2026) extended the AHCAH waiver to September 30, 2030, ending a 14-month period of repeated short-term extensions that had constrained capital allocation. Health systems can now plan multi-year capacity build-outs, and the leading indicator to monitor is the 1.3% reimbursement reduction CMS announced for 2026 (a US$220 million impact) which signals that rate-compression risk is the next watch-item.

Best Buy Health exit reframes operator landscape

Best Buy acquired Current Health for US$400 million in 2021 with the intent of leveraging Geek Squad in-home installation. By 2024, Best Buy had exited and sold Current Health back to its founder. The cited reasons were reimbursement uncertainty, slower-than-expected adoption, and clinical-integration complexity that exceeded the consumer-tech retail operating model. The category is now structurally favourable to operators with healthcare-system DNA.

Medicare Advantage supplemental-benefits scaling

CMS regulatory changes in 2020 enabled Medicare Advantage plans to offer hospital-at-home as a supplemental benefit beyond the AHCAH waiver. MA enrollment exceeded 33 million in 2025 and is projected to reach 40 million by 2030. MA plan-specific hospital-at-home contracts grew from a handful in 2022 to over 80 by end-2025, making the MA channel the highest-growth US payer segment through 2030.

Other relevant developments include the CMS Transforming Episode Accountability Model (TEAM) launched January 1, 2026 which aligns bundled-payment incentives with hospital-at-home delivery, and the Amedisys-Contessa selection as a Guiding an Improved Dementia Experience (GUIDE) Model participant in August 2024.

Competitive Landscape

The category is fragmented at the operator level but concentrated at the integrated health-system layer. Mass General Brigham, Atrium Health, Mayo Clinic, Cleveland Clinic, Geisinger, Jefferson Health, and Kaiser Permanente collectively run the largest US hospital-at-home volume, while Medically Home is the leading pure-play technology platform serving over 150 partner hospitals. Amedisys-Contessa brings home-health-conglomerate workforce-and-logistics infrastructure, anchored by the August 2024 GUIDE Model selection.

Key Policies and Regulatory Environment

CMS Acute Hospital Care at Home waiver

Originally launched November 2020. Required four short-term extensions before the Consolidated Appropriations Act of 2026 extended the framework to September 30, 2030. Payment is DRG-based at the same rate as inpatient. As of September 2025, 419 hospitals across 147 systems and 39 states have CMS approval. This is the binding US framework.

State Medicaid coverage

Twelve state Medicaid agencies cover hospital-at-home for fee-for-service enrollees: Arizona, Arkansas, Massachusetts, Michigan, New York, New Jersey, North Carolina, Oregon, Oklahoma, South Carolina, South Dakota, Texas. Coverage models vary, with some states using 1115 waivers and others using State Plan Amendments. Expansion to the remaining 38 states is the largest unaddressed payer-side opportunity through 2030.

Other relevant frameworks include the CMS Transforming Episode Accountability Model (TEAM, January 1, 2026), CMS Medicare Advantage supplemental-benefits flexibility (since 2020), the UK NHS @home virtual-wards programme targeting 500,000 patients per year by 2027, and Australia's Hospital in the Home framework dating to the 1990s.

Future Outlook

The category transitions from waiver-dependent pilot to standard care-delivery option. By 2032, US AHCAH-served Medicare FFS accounts for roughly 32% of the global category (down from 38% in 2024), Medicaid fee-for-service expands to 18% (from 8%), and Medicare Advantage to 22% (from 14%). The competitive landscape consolidates: we expect Medically Home, Biofourmis, and Inbound Health to be acquisition targets for home-health conglomerates, large hospital systems, or healthcare-tech platforms during 2026–28.

The single binding constraint shifts from regulation to workforce. The Bureau of Labor Statistics projects a 195,000 nursing-shortage gap by 2030, and hospital-at-home expansion competes with inpatient capacity for the same labour pool. Operators that resolve workforce-bottleneck through clinical-pathway flexibility (paramedics, advanced-practice nurses, hospital-at-home-trained generalist nurses) and reduced-burnout deployment models capture share. The leading risk to the outlook is a CMS payment-rate compression event in 2027–28; the announced 1.3% 2026 reduction is the leading indicator.